R E S EARCH AR TIC L E Open Access
ELISA versus PCR for diagnosis of chronic Chagas
disease: systematic review and meta-analysis
Pedro EAA Brasil1,2*, Liane De Castro1
, Alejandro M Hasslocher-Moreno1
, Luiz HC Sangenis1
, JosÃ© U Braga2,3
Abstract
Background: Most current guidelines recommend two serological tests to diagnose chronic Chagas disease. When
serological tests are persistently inconclusive, some guidelines recommend molecular tests. The aim of this
investigation was to review chronic Chagas disease diagnosis literature and to summarize results of ELISA and PCR
performance.
Methods: A systematic review was conducted searching remote databases (MEDLINE, LILACS, EMBASE, SCOPUS
and ISIWeb) and full texts bibliography for relevant abstracts. In addition, manufacturers of commercial tests were
contacted. Original investigations were eligible if they estimated sensitivity and specificity, or reliability -or if their
calculation was possible - of ELISA or PCR tests, for chronic Chagas disease.
Results: Heterogeneity was high within each test (ELISA and PCR) and threshold effect was detected only in a
particular subgroup. Reference standard blinding partially explained heterogeneity in ELISA studies, and pooled
sensitivity and specificity were 97.7% [96.7%-98.5%] and 96.3% [94.6%-97.6%] respectively. Commercial ELISA with
recombinant antigens studied in phase three investigations partially explained heterogeneity, and pooled sensitivity
and specificity were 99.3% [97.9%-99.9%] and 97.5% [88.5%-99.5%] respectively. ELISAâ€™s reliability was seldom
studied but was considered acceptable. PCR heterogeneity was not explained, but a threshold effect was detected
in three groups created by using guanidine and boiling the sample before DNA extraction. PCR sensitivity is likely
to be between 50% and 90%, while its specificity is close to 100%. PCR reliability was never studied.
Conclusions: Both conventional and recombinant based ELISA give useful information, however there are
commercial tests without technical reports and therefore were not included in this review. Physicians need to have
access to technical reports to understand if these serological tests are similar to those included in this review and
therefore correctly order and interpret test results. Currently, PCR should not be used in clinical practice for chronic
Chagas disease diagnosis and there is no PCR test commercially available for this purpose. Tests limitations and
directions for future research are discussed.
Background
Chagas disease is an infection, in which the necessary
cause is a parasite called Trypanosoma cruzi. This disï¿¾ease is endemic in Latin American countries and
approximately 15 million people are estimated to be
infected [1]. With progressive control of vector borne
transmission in the majority of Latin American counï¿¾tries,[1] much attention has been given to the possibility
of Chagas disease spread outside Latin America through
blood donation and/or organ transplants, due to the
increasing migration of Latin Americans around the
world [2]. Case reports of Chagas disease from countries
in which this infection is not typically endemic, such as
France[3], Canada[4-6], Switzerland[7], Denmark[8],
Germany[9], USA[10-12], and Spain[13,14] indicate that
in the appropriate clinical situation, Chagas disease
should be considered as differential diagnosis not only
in Latin Americans, but also in individuals who are not
from Latin America.
One significant difficulty in diagnosing Chagas disease
is that most patients have no symptoms in acute or
chronic phase [2,15,16]. Another difficulty in diagnosis
is that, unlike most infectious diseases, the direct or
parasitological tests for Chagas disease (thick or thin
* Correspondence: pedro.brasil@ipec.fiocruz.br
1
Instituto de Pesquisa ClÃ­nica Evandro Chagas - FundaÃ§Ã£o Oswaldo Cruz, Rio
de Janeiro/RJ, Brazil
Full list of author information is available at the end of the article
Brasil et al. BMC Infectious Diseases 2010, 10:337
http://www.biomedcentral.com/1471-2334/10/337
Â© 2010 Brasil et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.

smear, microhematocrit, hemocultures or xenodiagnosis)
have unacceptably low sensitivity in the chronic phase,
ranging from 50% to 70%,[17] and are not recomï¿¾mended [15-19]. Thus, the diagnosis relies almost solely
on serological tests.
Screening blood donors for Chagas disease is of much
concern in all Latin American countries. Although the
World Health Organization (WHO) expert committee
and some guidelines recommend a single enzyme linked
immunosorbent assay (ELISA) test to screen blood
donors,[16,18,19] in some countries, such as Brazil[15],
there is a more restrictive regulation, recommending
two simultaneous (in parallel) tests of different techniï¿¾ques. Due to potential transmission of Chagas disease
through blood transfusion, the United States of America,
Spain and other non Latin American countries also
screen blood donors for Chagas disease [20,21].
Currently, Pan-American Health Organization
(PAHO) recommendations[16] and other guidelines
[2,15,17,18] advise the use of two different serological
techniques for chronic Chagas disease diagnosis, one of
the techniques being ELISA. The basis of this recomï¿¾mendation is not clear, although some authors claim it
to be due to poor concordance between ELISA and
other serological tests,[22-25] and others claim it is due
to limited specificity [2]. It is known that ELISA tests, as
most tests used for screening purposes, may occasionally
lead to false positive results, which must be confirmed
later by other assays.
A pitfall of conventional ELISA is the possibility of
cross-reaction with antibodies from patients infected
with Leishmania sp. or T. rangeli [26-28]. This is a diffiï¿¾cult problem to solve where these infections share endeï¿¾micity with Chagas disease. In an attempt to overcome
these limitations, efforts were made to develop ELISA
with recombinant antigens (ELISA-rec) and polymerase
chain reaction (PCR) tests for Chagas disease.
Currently, PCR test may be recommended depending
on the situation and guideline considered. PCR test is
recommended for chronic Chagas disease diagnosis
only when serological tests are inconclusive by the
Brazilian and Chilean consensus; [15,17] may be
recommended only as confirmatory test after screening
of blood donors according to El Salvadorâ€™s guideline;
[16] it is recommended only for acute or congenital
infection diagnosis or therapy follow-up after acute
infection diagnosis according to WHO expert commitï¿¾tee[19] and a north American review;[2] and according
to Spanish consensus a patient is considered with Chaï¿¾gas disease either with two positive serological test or
PCR (or other parasitological) positive test when
chronic disease is suspected [18]. Thus, the use of
PCR tests for chronic Chagas disease diagnosis is
controversial.
The aims of this investigation were summarize sensiï¿¾tivity, specificity and diagnostic odds ratio (DOR) for
ELISA, ELISA-rec and PCR; evaluate the heterogeneity
within this literature for chronic Chagas disease; and
compare the overall accuracy of these three tests.
Methods
This investigation was designed as a systematic review
and meta-analysis.
Search strategies
Three bibliographic methods were used to identify potenï¿¾tial abstracts or investigations: remote search in electroï¿¾nic databases; bibliographic citations from included and
excluded full text retrieved from other search methods;
email contact with manufacturers that had any device or
diagnostic kit concerning Chagas disease registered at
ANVISA (AgÃªncia Nacional de VigilÃ¢ncia SanitÃ¡ria - or
the Brazilian National Agency of Sanitary Surveillance)
through October 2007. No hand search or contacts with
experts were made.
Electronic searches were executed in five different
databases on June 6th, 2007: PubMed/Medline; SCOPUS;
LILACS; ISIWeb/Web of Science; and EMBASE. The
following strategy was developed in PubMed/Medline
using clinical queries for diagnostic studies maximizing
the sensitivity of the search: ("Chagas Disease"[MeSH]
OR â€œTrypanosoma cruzi"[MeSH]) AND (ELISA OR
(enzyme AND linked AND assay) OR PCR OR (polymerï¿¾ase AND chain AND reaction))) AND (sensitiv*[Title/
Abstract] OR sensitivity and specificity[MeSH Terms] OR
diagnos*[Title/Abstract] OR diagnosis[MeSH:noexp] OR
diagnostic*[MeSH:noexp] OR diagnosis, differential
[MeSH:noexp] OR diagnosis[Subheading:noexp] OR
â€œReproducibility of Results"[Mesh] OR reliability OR
reproducibility). This strategy was adapted to the other
four bases and they were all updated on April 20th,
2009.
In December 2007, the ANVISA website http://www7.
anvisa.gov.br/datavisa/Consulta_Produto_correlato/conï¿¾sulta_correlato.asp was accessed to check for medical
products, devices or kits related to Chagas disease. At
the time, there were 52 registries, and only seven were
active. Since technical reports used to register these proï¿¾ducts are not available at ANVISA website, emails were
sent to manufacturers or their legal distributors requestï¿¾ing the technical report, monographs, non-published litï¿¾erature or a reference of a published report related to
their product.
Inclusion/exclusion criteria
The abstracts were eligible for full text evaluation if
their aims were: estimate sensitivity or specificity of one
or more ELISA or PCR for chronic Chagas disease;
Brasil et al. BMC Infectious Diseases 2010, 10:337
http://www.biomedcentral.com/1471-2334/10/337
Page 2 of 17

estimate accuracy of an ELISA or PCR for chronic Chaï¿¾gas disease; to test a new ELISA or PCR for chronic
Chagas disease; to estimate any validity measure for
ELISA or PCR for chronic Chagas disease such as likeliï¿¾hood ratios, accuracy, error rate, DOR, area under the
ROC (receiver operating characteristics) curve or predicï¿¾tive values; to estimate intra-test variability (reliability)
of a PCR or ELISA for chronic Chagas disease. Abstracts
with unclear objectives, but which partially met any of
the criteria above, or with unclear objectives and had
any of the validity measure (as described above) as a
result, were also included.
Abstracts indicating that the investigation was neither
conducted with human volunteers nor with samples
from human beings, or indicating that the tests were
studied in a verification of cure scenario were not
included. Investigations concerning exclusively acute
infection or newborns, or with mixed data from acute
and chronically infected patients were excluded.
After full text retrieval the following criteria were
applied for quality evaluation and data extraction: (a)
investigations should be original (no reviews, editorials
or letters); (b) should be quantitative investigations; (c)
every investigation must have two samples (one repreï¿¾senting those with chronic Chagas disease and one
representing those without chronic Chagas disease); (d)
must have results with enough data to allow extraction
(or calculation) of true positives, false negatives, false
positives and true negatives of each test. Only texts pubï¿¾lished after 1980 were included. Although only abstracts
in English, Spanish or Portuguese were accepted, no lanï¿¾guage restriction was applied to full text evaluation.
All diagnostic investigation phases were accepted.
Investigations were classified into these phases accordï¿¾ing to Haynes [29]. Briefly, studies were classified as (1)
phase 1 if they compared results distributions of those
known to have disease with those known not to have
disease, usually in small samples in which selection was
done by convenience or by previous knowledge of Chaï¿¾gas disease status; (2) as phase 2, if they estimated sensiï¿¾tivity and specificity (or predictive values) from study
designed as case-control, that could also use the same
data from a phase one study; (3) as phase 3, those stuï¿¾dies designed as cross-sectional with consecutive or ranï¿¾dom selection of the volunteers, where the main
inclusion criteria is based on the suspected chronic Chaï¿¾gas disease.
Index text and reference standard
The target condition of interest was chronic Chagas disï¿¾ease. Classifying Chagas disease according to infection
time (in acute and chronic) may be challenging. Usually
chronic Chagas disease means adults with long term
infection (ten years or longer), but the term may also be
applied to children, primarily with the indeterminate
form of the disease, with no history of acute fever
detected in the past two months. Original investigations
with children were also included if the authors did not
define their infection as either acute or chronic, and
there was no report of symptoms or signs compatible
with acute phase. Studies with children with one year
old or less were considered as acute infection studies.
All reference standards used by the authors of the oriï¿¾ginal investigations were accepted. This was based on
the rationale that for a long time, there was no â€˜gold
standardâ€™ for Chagas disease diagnosis accepted among
all experts. However, two or more simultaneous seroloï¿¾gical tests (with at least two different techniques) were
considered appropriate in the review quality assessment.
The index tests (tests under evaluation) of interest of
this research were ELISA, ELISA-rec and PCR.
From 1980 to 2010, ELISA technology has been widely
accepted and used due its automation and ease of use
(most of the tests are semi-automated). Its results are
less operator dependent, and are more readily available.
The basis of the test is to detect patient antibodies
against T. cruzi antigens. This serological test is a reacï¿¾tion in which an enzyme gives a colorful result if the
serum sample has the target anti-body, and it is
recorded in optical densities.
The most interesting variation is the ELISA-rec. This
variation does not use antigens made from lysates of
whole parasites. Instead, its antigens (peptides) are conï¿¾structed with recombinant technology. All variations
were included and discriminated.
PCR technique for Chagas disease is considered a
parasitological test such as thick or thin smear, xenoï¿¾diagnosis or hemocultures, because the test relies on
amplification of DNA (Deoxyribonucleic acid) target
sequences. The test is based on the detection of T. cruzi
DNA sequences in patientsâ€™ blood samples.
There are different PCR techniques (qualitative methï¿¾ods) for detecting T. cruzi DNA in patientsâ€™ blood samï¿¾ples are: â€œHot-Start PCRâ€ (a modification of
conventional PCR that should reduce nonspecific ampliï¿¾fication during the initial setup stages); â€œNested-PCRâ€
(two step amplification often used for very low amount
of DNA targets); â€œSouthern Blotâ€ or â€œPCR and hybridiï¿¾zationâ€ (a procedure used to verify the presence or
absence of a specific nucleotide sequence in the DNA
from patientsâ€™ blood samples by a labeled hybridization
probe).
In some analysis, it is important to detect the amounts
of pathogens, so as to indicate the disease severity or to
monitor therapy outcome of infected patients. The Realï¿¾Time PCR is based on the polymerase chain reaction
technology, used to amplify and simultaneously quantify
a targeted DNA molecule.
Brasil et al. BMC Infectious Diseases 2010, 10:337
http://www.biomedcentral.com/1471-2334/10/337
Page 3 of 17

There are primers for two main target regions of T.
cruzi DNA amplification: nuclear satellite DNA (nsï¿¾DNA) - a family of highly repetitive nuclear DNA
sequences named E13, that is distributed over most of
the parasite chromosomes;[30] and Kinetoplast DNA
(K-DNA) - part of the usual mitochondrial DNA found
in trypanosomes [31]. All these variations were included
and discriminated.
Review process
Research forms were designed and piloted for the purï¿¾pose of this review. Four blinded reviewers evaluated
abstracts and full text. One reviewer read and classified
all abstracts and eligible full text, and each one of the
remaining three reviewers reviewed and classified
approximately one third of the abstracts. Disagreement
among reviewers was resolved in consensus meetings
and tended to be inclusive if disagreement was persisï¿¾tent. In a similar way, two blinded reviewers classified
and extracted each full and disagreement was solved in
a consensus meeting.
Methodological quality assessment
The methodological quality of each included investigaï¿¾tion was also evaluated in a blinded fashion with QUAï¿¾DAS tool (QUality Assessment of Diagnostic Accuracy
Studies) [32,33]. A consensus meeting was conducted to
confirm agreement and to resolve disagreement between
reviewers about this issue.
QUADAS is a checklist to help readers assess key
issues about quality of conducting and reporting of diagï¿¾nostic test research, which will help in results interpreï¿¾tation. Its interpretation is rather qualitative, making
comparison of quality only possible through individual
items. Overall scores or grades may not help quality
interpretation and are not recommended [34-36].
Data analysis plan
The statistical analysis was based on the following steps
(figure 1): (1) qualitative description of findings; (2)
search for the presence of heterogeneity and a threshold
effect; (3) exploring possible explanations for heterogeï¿¾neity by sensitivity analysis; (4) statistical pooling. Teleï¿¾FormÂ® was used for data entry and analysis was carried
out with R-project software[37], with packages meta[38]
and DiagMeta [39].
One must understand heterogeneity as a greater variaï¿¾tion of sensitivity, specificity or DOR between the
included studies than is compatible with the play of
chance. This statistical heterogeneity should represent
other sources of heterogeneity such as: clinical characï¿¾teristics, tests characteristics or research design characï¿¾teristics. It was decided a priory that sources of
heterogeneity investigation would be conducted by
sensitivity analysis, in other words, changing inclusion
and exclusion criteria for sub-group analysis, including
and excluding one by one of the information available
(shown in Additional file 1, Additional file 2 and Addiï¿¾tional file 3 and others) such as: tests characteristics
(such as different antigens, different methods for estiï¿¾mating the cut-off, different DNA region targets etc);
sample or populations characteristics (such as age range,
sex, location; if studied in blood donors); and design/
report characteristics, including QUADAS items (such
as the reference standard, blinding, if submitted to
ethics evaluation etc.). Study phase and whether the test
was commercially available were of particular interest.
Heterogeneity was explored with I2 estimate [40]. I2
measures up to 25% were considered low evidence of
heterogeneity, between 25% and 50% with moderate hetï¿¾erogeneity, and 50% or higher with high heterogeneity.
The I2 was estimated in the sensitivity, specificity and
DOR measures.
Threshold effect was investigated as a source of hetï¿¾erogeneity and to check if pooling summary ROC was
appropriate. It was defined as a positive correlation
among true positive rate (TPR) and false positive rate
(FPR) - or a negative correlation among sensitivity and
specificity - and was explored in a HSROC model (Hierï¿¾archical Summary Receiver Operator Characteristics)
fitted by Maximum Likelihood (ML) and Monte Carlo
Markov Chain (MCMC) methods. If there was a moderï¿¾ate to high heterogeneity, correlation was explored, and
if positive, a HSROC was estimated by principal compoï¿¾nent of positive MCMC estimations[39] and plotted, if
negative or zero summary estimates were pooled withï¿¾out HSROC [39].
Summaries estimates - Sensitivity (or True Positive
Rate) and 1- Specificity (or False Positive Rate) - were
pooled using the random bivariate model, with Laplace
method for Maximum Likelihood (ML) and Monte
Carlo Markov Chain (MCMC) method [39]. Summary
DOR was estimated as the ratio of positive likelihood
ratio over negative likelihood ratio with DerSirmonian &
Laird random effect using the inverse variance technique
for sample size weight.
Results
Search results
From all five remote databases, 1349 abstracts were
retrieved. Following the removal of replicates, 713 were
found and evaluated (figure 1). After abstracts evaluaï¿¾tion only 183 were elected for retrieval of the full text.
Based on the strategy of email or telephone contact
with manufacturers or distributors, 15 out of 57
ANVISA registries were not used, either because some
were clearly not about ELISA tests or, in four cases,
because no email or phone contact could be found
Brasil et al. BMC Infectious Diseases 2010, 10:337
http://www.biomedcentral.com/1471-2334/10/337
Page 4 of 17

either at ANVISA registries, or in the World Wide Web.
From this strategy only four returned the request.
Abbott-Brazil returned the operational manual for
â€˜Chagas Test ELISA IIIâ€™, which was not considered a
report to be evaluated although there was some
sensitivity and specificity data. Lemos Laboratory
(Argentina) sent a reference published in 1998 conï¿¾taining data from Polychaco/Biozima-Chagas, which
was subsequently found in the remote databases
search.
$EVWUDFWVLQ
UHPRWHGDWDEDVHVXS
WR$SULO
$EVWUDFWVHOHFWHG

5HIHUHQFHV
IURPELEOLRJUDSK\
FLWDWLRQVEDFNWR
1RWIRXQG
1RWWUDQVODWHG

)XOOWH[WV
UHWULHYHG
'LGQRWPHHW
FULWHULD
0HHWFULWHULD
(/,6$ ZLWK
UHFRPELQDQW
DQWLJHQV
$EVWUDFWV HYDOXDWLRQ
)XOOWH[WV HYDOXDWLRQ
%\WHVWRILQWHUHVW
5HSRUWIURP
PDQXIDFWXUHU
(/,6$ZLWK
UHJXODUDQWLJHQV

3RO\PHUDVH
&KDLQ5HDFWLRQ

'XSOLFDWHG
GDWD
'DWDDQDO\VLVSODQ
$VVHVVKHWHURJHQHLW\,
LQHDFKWHVW
([SORUHKHWHURJHQHLW\YDULDWLRQ, 
E\VHQVLWLYLW\DQDO\VLVHJIRUPLQJVXEJURXSV
GHILQHGE\GLIIHUHQWWHVWVVDPSOHRUPHWKRGRORJ\FKDUDFWHULVWLFVDQGVHDUFKIRU
WKUHVKROGHIIHFWLQHDFKWHVW
3RROVXPPDU\HVWLPDWHVELYDULDWHUDQGRPPRGHOLQJURXSVRUVXEJURXSVLI
KHWHURJHQHLW\LVDEVHQWRUSDUWLDOO\H[SODLQHGSRRO+652&LIWKUHVKROGHIIHFWLV
SUHVHQW
Figure 1 Flowchart of abstracts and full texts evaluation and data analysis plan. Several full texts evaluated two or more tests; therefore
the sum of tests with data extracted is not equal to the total of full text included.
Brasil et al. BMC Infectious Diseases 2010, 10:337
http://www.biomedcentral.com/1471-2334/10/337
Page 5 of 17

Ebram Laboratory returned the email stating that they
did not have any technical report at the time, and the
only validation process was executed by CGLAB (NÂ° 03/
06) (CoordenaÃ§Ã£o Geral de LaboratÃ³rios de SaÃºde PÃºbï¿¾lica - or General Coordination of Public Health Laboraï¿¾tories, which is a coordination in the Brazilian
Epidemiologic Surveillance Department). http://portal.
saude.gov.br/portal/arquivos/pdf/nota_kit_chagas.pdf
However, this note could not be considered for evaluaï¿¾tion because there was no data for extraction and no
information to evaluate the quality of the investigation.
Orgenics sent a non-published report about the
â€˜ImmunoComb II Chagas Ab kitâ€™. Although described as
a conventional ELISA, this test is formatted as a strip or
rapid test. Even described as a multicenter evaluation,
each center was considered a single report due to sevï¿¾eral protocol differences in each center. This report was
the only one included from the manufacturer email conï¿¾tact search strategy.
Another concerning issue is that five out of the twelve
commercial kits tested by CGLAB in 2006 were not
found in the ANVISA list of registered medical products
captured in 2007, nor were their reports found through
other search strategies.
Thirty three references, that were not captured by
remote databases search, were identified throughout bibï¿¾liography of 2 narrative reviews[41,42] and other origiï¿¾nal investigations. Therefore, there were 217 full texts
elected for assessment. (figure 1)
After applying inclusion/exclusion criteria, 114 texts
were excluded, 4 of them were discarded due duplicated
data in different reports by the same author - leaving
103 texts for data extraction. Several reports had data
from two or more tests simultaneously; therefore, there
were 115 regular ELISA reports[22,25,43-105] (Addiï¿¾tional file 1), 49 ELISA-rec reports [22,23,61,76,
79,80,85,90,92,97,98,103,106-116] (Additional file 2) and
21 PCR reports[26,100,117-130] (Additional file 3), genï¿¾erating 185 tests results to analyze (figure 1).
Methodological quality of included studies
Quality of included original investigations was assessed
with QUADAS (Additional file 4). Only 8 (4.3%) investiï¿¾gations were considered to have clear inclusion criteria.
Sixty three investigations (33.9%) were classified as
using a reference standard likely to correctly classify
Chagas disease. In 93 investigations (50.0%) it was clear
that the whole sample received verification using the
reference standard. In 106 investigations, it was clear
that patients received the reference standard regardless
of index text result. In 132 (71.0%) investigations, it was
clear that the reference standard was independent from
the index test. In 124 (66.7%) and 33 (17.7%) investigaï¿¾tions, the index test and the reference standard
respectively were clearly described. In 22 (11.8%) stuï¿¾dies, index test or reference standard blinding was cited,
but only in 18 (9.7%) were both included. In 20 (10.8%)
studies, inconclusive index test results appeared to be
omitted and in 19 (10.2%) withdrawals were not
explained.
Findings
There was a lot of information not available about cliniï¿¾cal characteristics and sample description of the 185
tests from original investigations. (Additional file 1,
Additional file 2 and Additional file 3) Only 20 (10.8%)
specified the recruitment period, 31 (16.7%) specified
the proportion of children in its sample, 28 (15.1%) speï¿¾cified the sex distribution, 32 (17.2%) specified age
range, in 69 (37.1%) it was not possible to determine if
there were blood donors in the sample, in 163 (87.6%)
and 167 (89.8) it was not possible to determine if people
living in rural or urban area respectively were included
in the sample, in 26 (14.0%) the sample was composed
exclusively of blood donors, in only 21 (11.3%) there
was some information about clinical characteristics such
as cardiac or digestive involvement, or disease severity,
and in 31 (16.7%) submission to review board and ethics
evaluation was reported
Eighty one investigations were conducted in Brazil, 24
in Argentina and the remaining were conducted in sevï¿¾eral other countries in Latin America, USA or Spain. In
9 (4.8%), it was not possible to determine where the
protocol was conducted or from where included
patients/samples were.
Concerning only the ELISA group, two tests were
based on strip (rapid test) technology, in 76 (46.1%)
tests it was not specified how the cut-off was estimated
and only in 11 (6.7%) the cut-off estimation somehow
considered the distribution of results of those with the
target disease. In 143 (86.7%), it was not specified if
there was an inconclusive range; in 110 tests (66.7%),
the value of the cut-off was not specified.
In regular ELISA group, the strain used to extract
antigens for the test was not specified in 68 (58.2%), and
in all the commercial tests this information was not
available; in 59 (50.7%) tests the T. cruzi life cycle form
used as sources of antigens was not specified, and in 65
(56.0%) antigen purification was not specified or not
clear in the report.
From the 186 tests evaluated, only 60 (32.4%) were
specified to be commercially available. From these, 3
(5.0%) were classified as phase 1, 49 (81.7%) were classiï¿¾fied as phase two, and only 8 (13.3%) were classified as
phase 3.
Concerning the PCR group (Additional file 3), one
protocol specified 3 blood samples collections from the
same patients, four did not inform how many samples
Brasil et al. BMC Infectious Diseases 2010, 10:337
http://www.biomedcentral.com/1471-2334/10/337
Page 6 of 17

were collected and the remaining collected one blood
sample; blood volume collected in each sample ranged
from 1 ml to 15 ml; six did not inform storage condiï¿¾tion and none informed time gap between blood collecï¿¾tion and DNA extraction; ten studies added guanidine
and boiled the blood samples before DNA extraction,
five studies added guanidine and did not boiled the
blood samples, five studies did not add guanidine
neither boiled before DNA extraction, and in one study
guanidine addition and boiling information was not
available; extracted volume from each sample ranged
from 100 Î¼l to 500 Î¼l and two studies did not inform
extraction volume; eighteen studies used phenol-chloroï¿¾form, two used commercial kits for DNA extraction and
one did not inform DNA extraction procedure; eleven
did not inform inhibition control procedure; eight did
not inform contamination control procedure; only three
studies informed analytical sensitivity; fourteen studies
used primers aiming K-DNA and four studies used priï¿¾mers aiming ns-DNA; sixteen studies used protocols of
regular PCR, three studies used hybridization PCR, one
used a nested PCR and one used a real-time and nested
PCR; annealing temperature ranged from 55Â°C to 65Â°C.
All PCR tests were classified as in-house and 7 different
combinations of primers were used. (Additional file 5)
Heterogeneity within each of the three tests (ELISA,
ELISA-rec and PCR) was very high. (Additional file 6)
In none of the groups explored, heterogeneity was fully
explained. Also, threshold effect within the three tests
was absent, which makes HSROC estimates or compariï¿¾son of curves between them not appropriate.
In the ELISA group, those tests that registered a
blinded evaluation of the reference standard (QUADAS
11 = Yes) had moderate heterogeneity in sensitivity,
moderate to high heterogeneity in specificity and little
evidence of heterogeneity in DOR. A threshold effect
was detected (Additional file 7) in this group and
HSROC was considered appropriate. (figure 2) Within
this subgroup, summary sensitivity and specificity were
97.7% and 96.3%, respectively. (Additional file 7)
Five commercial ELISA tests were classified as phase 3
and although there was high heterogeneity in sensitivity
and specificity, it was moderate in DOR. (Additional file
5) Figure 3 shows forest plots of this group and the
summary sensitivity was 94.3% and specificity was
99.9%. (Additional file 7)
Similar to ELISA group, heterogeneity was very high
in ELISA-rec. (Additional file 6). Within this group, only
three commercial tests were classified as phase 3. In
commercially available ELISA-rec tests investigated in
phase 3 studies, heterogeneity was high in specificity,
and low evidence was found in sensitivity and DOR.
Threshold effect was not estimated due to difficulties of
convergence of HSROC model, thus it was not
considered appropriate. Summary estimates by bivariate
random model are 99.2% and 97.5% for sensitivity and
specificity respectively (Additional file 7). Forest plots
for this subgroup are displayed in figure 4.
Analysis of a subgroup of commercial ELISA (regular
and recombinant) investigated in phase 3 studies that
used only blood donors in the sample demonstrated
that only six studies fit these criteria. Heterogeneity was
very high in all three measures and a threshold effect
was not detected.
PCR has a below desired sensitivity (probably between
50% and 90%) and very high specificity (probably very
close to 100%). Heterogeneity was very high and no
variable explored was able to explain it. In the three
validity estimates considered, I2 is always over 70.0%.
(Additional file 6) This means that from all available
data, there was not a particular PCR feature that could
explain the observed differences in PCR performance,
thus pooling summary estimates by any PCR characterï¿¾istics (such as DNA target region) was not considered
appropriate. However, a threshold effect was detected in
subgroups composed by two variables: test with samples
stored with guanidine (yes or no) and boiled before proï¿¾cessed (yes or no). In the three groups formed by this
combination, the heterogeneity still remained very high
in some pooled estimates. (Additional file 6) Sensitivity
and specificity summaries are displayed in Additional
file 7.
At first it seems that the group â€˜stored with guanidine
and boiledâ€™ has a better performance, with sensitivity of
Figure 2 Regular ELISA for Chagas disease summary ROC for
tests with blinded reference standard evaluation. Dots - crude
estimates; filled black squares - shrunken estimates from bivariate
model; filled red circle - bivariate model summary estimate; black
solid line - SROC curve.
Brasil et al. BMC Infectious Diseases 2010, 10:337
http://www.biomedcentral.com/1471-2334/10/337
Page 7 of 17

92.2% and specificity of 97.7%, while the other two
groups have sensitivity close to 50% and specificity close
to 100%. However, the summary curve of the former
group is almost identical to the group â€˜not stored with
guanidine and not boiledâ€™ while accuracy is lower for
the group â€˜stored with guanidine and not boiledâ€™. (figure
5) Also, it seems that all three curves have smaller areas
when visually compared to the ELISA curve. (figure 2)
In the Chagas diagnostic literature there is a sense
that reliability of serological tests is less than the desired
level, however this review was able to identify only 7
investigations showing some result regarding reliability
and in all of them the estimates are in acceptable levels
(Additional file 1 and Additional file 2), and surprisingly
no reliability was formally tested in any PCR
investigation.
Discussion
In the beginning of this review there was an interest in
phase 3 investigations with commercially available tests,
which are believed to have results more easily
interpreted and are more readily available for use in
clinical practice. However, the attempt to include techï¿¾nical reports from commercially available tests was not
very successful, because only one non-published report
was accessed and it seems that some commercial tests
reports do not exist or are not accessible.
Recent Brazilian regulations states that medical proï¿¾ducts or devices do not need technical reports if they
are used in vitro - for example, used on any patientâ€™s
material such as blood, sputum, urine etc. - although
they may be closely related to medical decision making.
We wonder why technical reports are not available from
regulatory register. Despite the reasons, their ability to
correctly identify those with and without Chagas disease
is unknown for those who use those tests in clinical
practice.
Because of some perceptions during the review, such
as: few phase three investigations; few commercial tests
investigations sponsored by manufacturers; reports pubï¿¾lished mainly in immunology and parasitology journals;
absence of products monographs or technical reports; as
Figure 3 Forest plots of sensitivity (A), specificity (B) and DOR (C) for phase 3 studies investigating commercial ELISA tests. Events -
identified as with Chagas disease by the test; OR - (diagnostic) odds ratio; proportion - sensitivity (or specificity) individual point estimate; Total -
number of subject within each sample (with or without Chagas disease); W - weights.
Brasil et al. BMC Infectious Diseases 2010, 10:337
http://www.biomedcentral.com/1471-2334/10/337
Page 8 of 17

well as the amount of missing information is considerï¿¾ably higher in the commercial tests reports; it seems
that in this field there is a considerable gap between the
academic production, manufacturer interests and clinical
practice.
Methodological quality of original reports was assessed
through QUADAS tool. A careful reader would soon
understand that QUADAS was developed to evaluate
investigations in a more clinical scenario, for example,
phase 3 investigations. Several issues such as gold stanï¿¾dard description, inclusion and exclusion criteria and
blinding assessment are perhaps less important in phase
2 than in phase 3, therefore the use of QUADAS could
give a more strong impression of poor quality of the
included investigations in this review, since the majority
of original investigations were classified as phase 2.
The overall impression regarding methodological qualï¿¾ity of included reports in this review is that poor quality
of reporting is mixed with poor quality of investigations
in most cases. This impression does not come solely
from the level of â€œuncertaintyâ€ in QUADAS evaluation,
but also from the amount of missing information about
sample description and test description. Even in those
investigations classified as phase 3, very few seem to folï¿¾low current recommended standards for report formats
[131].
Serological tests were seldom formally evaluated in
phase three investigations with samples exclusively from
blood donors. Although screening occurs in a different
setting from diagnosis in clinical practice, the same tests
are used and therefore the same problems are also
found, such as high heterogeneity, and absence of a
threshold effect. Particularly, in blood banks, the inforï¿¾mation about cut-off would be important because its
variation may be a simple mean by which test accuracy
could be improved. However, none of the phase three
studies using exclusively blood donors described which
test cut-off was used.
ELISA test results are generated as optical densities,
which are presented as a continuous scale. However,
none specified the area under the ROC curve (which is
considered an accuracy measure independent from the
Figure 4 Forest plots of sensitivity (A), specificity (B) and DOR (C) for phase 3 studies investigating commercial ELISA with
recombinant antigens. Events - identified as with Chagas disease by the test; OR - (diagnostic) odds ratio; Proportion - sensitivity (or specificity)
individual point estimate; Total - number of subject within each sample (with or without Chagas disease); W - weights.
Brasil et al. BMC Infectious Diseases 2010, 10:337
http://www.biomedcentral.com/1471-2334/10/337
Page 9 of 17

cut-off used), and very few investigations used strategies
to estimate a good cut-off considering both the distribuï¿¾tion of results of those with and without the target disï¿¾ease, such as maximizing Youdenâ€™s index. The majority
of specified cut-off, when specified, was estimated by
strategies such as â€˜mean of negative controls plus 2
standard deviationsâ€™, which may maximize specificity but
completely ignores sensitivity.
It is known that, similar to other infectious agents,
there are differences of circulating strains in different
geographic regions in Latin America [132]. Authors
from Colombia,[95,133] Peru,[134] and Mexico [87]
Figure 5 PCR for Chagas disease HSROC - subgroups of blood samples boiled before processed and stored with guanidine. Big blue
upside down triangle - summary estimate of the group stored with guanidine and boiled; Big green diamond - summary estimate of the group
stored with guanidine and not boiled; Big red triangle - summary estimate of the group not stored with guanidine and not boiled; Blue small
squares and blue small upside down triangles - shrunken estimates from bivariate model and crude estimates (respectively) from group stored
with guanidine and not boiled; blue solid line - SROC curve from group stored with guanidine and boiled; dot - crude estimates; small green
squares and small green diamonds - shrunken estimates from bivariate model and crude estimates (respectively) from group stored with
guanidine and not boiled; solid green line - SROC curve from group stored with guanidine and not boiled; small red squares and small red
triangles - shrunken estimates from bivariate model and crude estimates (respectively) from group not stored with guanidine and not boiled; red
solid line - SROC curve from group not stored with guanidine and not boiled; NA - not assigned or missing.
Brasil et al. BMC Infectious Diseases 2010, 10:337
http://www.biomedcentral.com/1471-2334/10/337
Page 10 of 17

showed that commercial tests may have worst perforï¿¾mances when compared to in-house tests with antigens
made from local T. cruzi strains. There were some mulï¿¾ticenter studies included in this review but the informaï¿¾tion about the antigen geographic source or stratified
analysis by center was sparse, turning impossible to
explore this issue as source of heterogeneity.
In Chagas diagnostic literature, researchers have
repeatedly said that there is a lack of reliability or agreeï¿¾ment of serological tests based on imperfect kappa estiï¿¾mated between different tests or laboratories
[22-25,67,89,95,135]. Therefore, there is a difference of
conceptions when comparing reliability definitions in
general statistics[136] or diagnostic test methodology litï¿¾erature,[131] where instrument variability concerns the
amount of variation that arises during the operation of
devices or systems, such as automated laboratory meaï¿¾surements. Other terms for this form of variation
include imprecision, reproducibility, analytic methodoloï¿¾gical variation, or analytical noise (error) and sometimes
calibration [137]. Because this review did not find high
intra-test variability of ELISA test, there is no evidence
to support the lack of reliability statement.
It appears that there is no widely accepted PCR test
protocol, since none of the tests found in literature used
identical protocols. This may indicate that the PCR for
T. cruzi is difficult to standardize and perhaps all protoï¿¾cols used are prone to some unacceptable procedure
errors for clinical diagnosis. Most PCR protocols still
use phenol-chloroform for DNA extraction instead of
available commercial kits. (Additional file 3) Phenolï¿¾chloroform has biohazards issues and is no longer
recommended for use in clinical laboratory routine or in
hospital settings.
Also, primers aiming K-DNA were the most freï¿¾quently used. Although these primers aim at conserved
regions within K-DNA, the amplified region is considï¿¾ered hypervariable[138] leading to variations in the
amplicon sizes. A possible problem with the K-DNA,
which was seldom investigated, is that the primer
annealing sequences are conserved within Kinestoplasï¿¾tida order [138]. However, sequence alignment of â€œ121â€
and â€œ122â€ analysis by comparing the â€œ121â€ and â€œ122â€
primers sequence with T. rangeli homologous region
(GeneBank: http://www.ncbi.nlm.nih.gov - access numï¿¾ber: L28038.1) showed that these primers cannot effiï¿¾ciently amplify the target from this specie due to
mismatches in the 3â€™ end of the primer, therefore the
possibility of T. rangeli miss-amplification is remote.
The different primer sequences used in the molecular
tests could be responsible for the observed test heteroï¿¾geneity. There was seven different set of primers used in
the twenty one included studies. Most studies applied
primer sequences targeted to K-DNA and ns-DNA. The
intention is to increase analytical sensitivity, as these are
repetitive regions in T. cruzi DNA. Also, primers for Kï¿¾DNA are slight modifications from one another within
the same target region, which suggests that these priï¿¾mers may have limitations for T. cruzi DNA
amplification.
It was not possible to explore the observed variation
of primers as source of heterogeneity due to the number
of groups that used different sets of primers, and some
primers were used only once. This review did not find
any evidence of superior analytical sensitivity of a partiï¿¾cular primer while most of the included studies did not
report this information.
Some authors stated that there is no clear advantage
and there are some disadvantages in using guanidine
over EDTA before extraction [139,140]. In hospital setï¿¾tings where samples could be processed, and DNA
could be extracted in the very same day, perhaps this
would no longer be necessary. Boiling the blood sample
before DNA extraction was also commonly described. It
has been shown that boiling during 15 minutes disrupts
the K-DNA minicircle nets, thus facilitating the homoï¿¾geneous distribution of minicircle molecules in all the
volume of Guanidine-EDTA treated sample and improvï¿¾ing primer annealing to the templates, thus allowing
processing of small volumes with high sensitivity. Howï¿¾ever, his review did not find evidence that this proceï¿¾dure increases PCR performance.
PCR success depends on the amount of circulating
parasites in patientsâ€™ blood stream. T. cruzi circulates in
very small amounts at the chronic phase and dynamics
about its circulation is not predictable [141,142]. It is
possible that, even if a patient is infected, the collected
sample does not have an adequate amount of the paraï¿¾site DNA leading the test to a negative or undetectable
result. A possible solution to this limitation is the collecï¿¾tion of several serial blood samples at different times
[126] or increasing the blood volume per test may overï¿¾come this problem.
Although this review has not intended to evaluate any
test to assess parasitological cure of Chagas disease, in
recent literature addressing this issue there is much disï¿¾cussion about PCR techniques for detecting trypanocidal
therapy outcome, primarily the real-time PCR [143,144].
This reflects the fact that serological markers and cliniï¿¾cal disease progression may take decades to be observed.
However, this review found no evidence that PCR tests
are adequate to correctly identify (mainly) the presence
of T. cruzi DNA. Perhaps PCR tests could be a suitable
tool to detect therapy outcome, in particular therapy
failure, but this remains to be evaluated in prospective
studies.
In 2007, TDR (a Special Program for Research and
Training in Tropical Diseases) launched an international
Brasil et al. BMC Infectious Diseases 2010, 10:337
http://www.biomedcentral.com/1471-2334/10/337
Page 11 of 17

multicenter study to standardize PCR procedures with a
panel of samples. The results of such study were anaï¿¾lyzed in a workshop with experts in which consensus
recommendations to run PCR for T. cruzi were formuï¿¾lated. This can be assessed in http://apps.who.int/tdr/
svc/publications/tdrnews/issue-82/meeting-chagas. Its
clinical usefulness, however still remains to be evaluated.
Review limitations
The main limitations of this review are: (1) inability to
find unpublished technical reports from tests commerï¿¾cially available, therefore this review may not represent
all ELISA tests or might have biased results; (2) sumï¿¾mary estimates were pooled from selected subgroups
where heterogeneity was partially explained, therefore
interpretation of results are less straight forward then a
result where heterogeneity is absent.
The quality of a systematic review is also influenced
by the original investigationsâ€™ quality. It is likely that
other items not explored by this review could explain
the observed heterogeneity. Examples of these items are:
data collection period; proportion of children in sample;
sex distribution in sample; sample median age; age
range; if volunteers were from rural or urban area; geoï¿¾graphical origin of volunteers; Chagas disease clinical
presentation such as cardiac or intestinal involvement;
ELISA generation; methods of preparations of antigens,
buffers or brand of plates; type of antibodies used; how
cut-off was estimated; indeterminate range; T. cruzi life
cycle form (epimastigote, trypomastigote etc) used as
source of antigen; geographical areas of the strains used
as source of antigens; inhibition control for PCR, conï¿¾tamination control for PCR, time gap between sample
collection and DNA extraction, maintenance condition
of the sample; polymerase trademarks; type of hybridizaï¿¾tion technique (colorimetric or radioactive); primer varï¿¾iation; inhibition
Many of these characteristics were not explored as
heterogeneity source because of the amount of original
investigations that did not report them, but other made
sensitive analysis difficult because many subgroups had
a single study.
Conclusions
ELISA and ELISA-rec performances are good. Their
reliability is within acceptable ranges although not often
studied. These findings lead to the conclusion that
recommendations to use two simultaneous serological
tests is based on mistrust in recommending a single test
that will fail very occasionally, or on a misunderstanding
of the reliability concept of diagnostic tests. Both ELISA
and ELISA-rec could be used as a single test for chronic
Chagas disease diagnosis, but caution is necessary while
some commercial tests technical reports were not
assessed by this review, thus they were not included and
their performance are not known.
This review results about PCR test are less conclusive
then ELISA, thus more difficult to interpret. Besides
strong evidence of heterogeneity, only one study was
classified as phase 3. Currently PCR performance is
below desired and its reliability has not been characterï¿¾ized. Visual comparison of the area under the summary
ROC curves for ELISA and PCR indicates that ELISA
has better performance than PCR. At this point, PCR
test cannot be considered a tool for diagnosis of chronic
Chagas disease in clinical practice.
Final considerations
There are many investigations about chronic Chagas
disease diagnosis since 1980, however little knowledge
reached clinical practice with current recommended
standards up to 2009. Phase 3 investigations and comï¿¾mercial tests detailed reports are necessary, and they
should follow standard report format,[131] always makï¿¾ing explicit: test reliability (intra-test agreement); if
reference standard and index test were blinded to each
other; volunteer selection strategy, mainly if it was based
on clinical suspicion of disease or not; clear description
of clinical characteristics of the volunteers; the cut-off
used and indeterminate range of the test and how they
were estimated; also, always include key issues of test
protocol, such as strains used in antigens development,
or which strains would the recombinant antigens could
represent, and antigen purification. Regulatory agencies
would make a great step forward if diagnostic testsâ€™
technical reports would be always necessary for product
registry and always available to the public.
Besides the quality of reports and design of diagnostic
research, there are points that could be addresses to
improve tests in the future. Serological tests could have
a set of recombinant or crude antigens combination
which could equally detect different T. cruzi strains
from distant geographic areas, in order to have similar
performance with patients from different locations. The
development and improvement of strip tests, or portable
tests, may be very useful, while the majority of patients
may be at distant rural areas where health care access is
difficult. Also, Chagas disease pathophysiolgy further
understanding may help to improve serological tests
while these tests aim to detect patientâ€™s antibodies, thus
there are patientsâ€™ characteristics that may influence serï¿¾ological tests performances.
Concerning PCR, much more is yet to be done. Incorï¿¾poration of modern techniques already available for
PCR to other diseases diagnosis (for example: HBV, HIV
and tuberculosis), such as commercial DNA extraction
kits, real-time and other techniques that could make the
test more automated should be encouraged. In addition,
Brasil et al. BMC Infectious Diseases 2010, 10:337
http://www.biomedcentral.com/1471-2334/10/337
Page 12 of 17

research on updated DNA sequence for PCR primers
design and use of multiple primer sets including multiï¿¾plex PCR test and primers aiming to parasiteâ€™s DNA
inserted into host genome should be encouraged. Also,
it is expected that performing a serial tests in a patient
and defining the diagnosis after assembling all the
results would increase test sensitivity.
Additional material
Additional file 1: ELISA for chronic Chagas disease descriptive
summary - test characteristics; population/sample characteristics
and test validity measures. 2/3-: two negative tests out of three; 2/3+:
two positive tests out of three; CF or CFR: complement fixation reaction;
CML: complement mediated lyses; CO Method: method to estimate the
cut-off; DA: direct agglutination; ELISA: enzyme linked immunosorbent
assay; Exclusively BB: investigation sample composed exclusive by blood
donors; Gray zone: test scale inconclusive range; IHA and HA: (indirect)
hemmagglutination; IIF: indirect immunefluorescence; IPR:
immuneperoxidase reaction; -MEAN or +MEAN: mean values from those
without or with Chagas disease respectively; NA: not assigned or missing;
OD: optical densities; PHA: passive hemagglutination; Reliability: intra-test
agreement; RIPA: radio-immune-precipitation assay; ROC: receiver
operator characteristic; RPHA: reverse passive hemagglutination; RS1 and
RS0: reference standard for subjects classified with and without Chagas
disease respectively; SD: standard deviation; SE: standard error; WB:
western blot; year: year of publication
Additional file 2: ELISA with recombinant antigens for chronic
Chagas disease descriptive summary - test characteristics;
population/sample characteristics and test validity measures. 2/3-:
two negative tests out of three; 2/3+: two positive tests out of three; CF
or CFR: complement fixation reaction; CO Method: method to estimate
the cut-off; Exclusively BB: investigation sample composed exclusive by
blood donors; Gray zone: range of test scale where results are
considered inconclusive; IHA and HA: (indirect) hemmagglutination; IIF:
indirect immunefluorescence; -MEAN or +MEAN - mean values from
those without or with Chagas disease respectively; NA: not assigned or
missing; OD: optical densities; PA: passive agglutination; Reliability: intraï¿¾test agreement; RIPA: radio-immune-precipitation assay; RS1 and RS0:
reference standard for subjects classified with and without Chagas
disease respectively; SD: standard deviation; SE: standard error; year: year
of publication.
Additional file 3: PCR for Chagas disease descriptive summary - test
characteristics; population/sample characteristics and test validity
measures. 2/2-: two negative tests out of two; 2/2+: two positive tests
out of two; ELISA - enzyme linked immunosorbent assay; Exclusively BB -
investigation sample composed exclusive by blood donors; HA -
hemagglutination; IIF - indirect immunefluorescence; K-DNA - kinetoplast
deoxyribonucleic acid; NA - not assigned or missing; ns-DNA: nuclear
satellite DNA; PCR - polymerase chain reaction; Reliability: intra-test
agreement; RS1 and RS0 - reference standard for subjects classified with
and without Chagas disease respectively; year - year of publication.
Additional file 4: Quality assessment with QUADAS tool of all tests
evaluated. Reader must refer to QUADAS full questionnaire for a
comprehensive interpretation of this table.
Additional file 5: Primers used in PCR tests in each of the original
investigations reviewed. *Intermediate products.
Additional file 6: Heterogeneity (I2
) estimates and its 95%
confidence limits for ELISA, ELISA-rec, PCR and selected subgroups.
DOR - diagnostic odds ratio; ELISA - enzyme linked immunosorbent
assay; ELISA-rec - ELISA with recombinant antigens; inf cl - inferior
confidence limit; N - number of tests included in subgroups; PCR -
polymerase chain reaction; Se - sensitivity; Sp Specificity; sup cl - superior
confidence limit.
Additional file 7: Summary Sensitivity and Specificity estimated by
bivariate random model in selected subgroups. ( ): number of tests in
each group; FPR: False positive rate or 1-Specificity; MCMC: Monte Carlo
Markov Chain; ML: Maximum likelihood; Reff: Random effect; SD:
Standard deviation; TPR: True positive rate or Sensitivity; upper and lower:
95% confidence limits.
Additional file 8: List of excluded papers and comments about
reasons of exclusions.
Additional file 9: Chart with strategies used on remote databases
search.
Acknowledgements
Thanks to Dr Valdilea Veloso, director of Instituto de Pesquisa Clinica
Evandro Chagas to financial support in accessing some full text; to Dr. Daria
Kiselica, Leonardo de Castro Monteiro and Thais Pereira Monteiro for English
review; to Mr Alejandro Schijman and Mr Richard Reithinger for valuable
suggestions for draft improvement while in peer review. List of excluded
papers and comments about reasons of exclusions is available (Additional
file 8). Additional search strategies in electronic databases are available
(Additional file 9).
Author details
1
Instituto de Pesquisa ClÃ­nica Evandro Chagas - FundaÃ§Ã£o Oswaldo Cruz, Rio
de Janeiro/RJ, Brazil. 2
Instituto de Medicina Social - Universidade do Estado
do Rio de Janeiro, Rio de Janeiro/RJ, Brazil. 3
Centro de ReferÃªncia Professor
HÃ©lio Fraga - Escola Nacional de SaÃºde PÃºblica - FundaÃ§Ã£o Oswaldo Cruz,
Rio de Janeiro/RJ, Brazil.
Authorsâ€™ contributions
PEAAB carried out the design, coordination, project/protocol development,
review, data analysis, draft development, LDeC was a reviewer and draft
reviewer, AMHM was a reviewer and draft reviewer, LHCS was a reviewer
and draft reviewer, JUB was involved in project development and draft
review. All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 16 December 2009 Accepted: 25 November 2010
Published: 25 November 2010
References
1. Moncayo A, Silveira AC: Current epidemiological trends for Chagas
disease in Latin America and future challenges in epidemiology,
surveillance and health policy. Mem Inst Oswaldo Cruz 2009, 104(Suppl
1):17-30.
2. Bern C, Montgomery SP, Herwaldt BL, Rassi A Jr, Marin-Neto JA, Dantas RO,
Maguire JH, Acquatella H, Morillo C, Kirchhoff LV, et al: Evaluation and
treatment of chagas disease in the United States: A systematic review.
Journal of the American Medical Association 2007, 298:2171-2181.
3. Le Loup G, Lescure FX, Develoux M, Pialoux G: Chagas disease: clinical
aspects and treatment in non-endemic countries. Presse Med 2009,
38:1654-1666.
4. Wendel S, Gonzaga AL: Chagasâ€™ disease and blood transfusion: A new
world problem? Vox Sanguinis 1993, 1:1-12.
5. Steele LS, MacPherson DW, Kim J, Keystone JS, Gushulak BD: The seroï¿¾prevalence of antibodies to Trypanosoma cruzi in Latin American
refugees and immigrants to Canada. J Immigr Minor Health 2007, 9:43-47.
6. Lane DJ, Sher GA, Ward B, Ndao M, Leiby D, Hewlet B, Bow E: Investigation
of the second case of transfusion transmitted chagas disease in Canada.
Blood 2000, 96.
7. Jackson Y, Chappuis F, Loutan L: Chagas disease in Switzerland: Managing
an emerging infection and interrupting its transmission. Rev Med Suisse
2008, 4:1212-1217.
8. Enemark H, Seiboek MB, Kirchhoff LV, Jensen GB: Chronic Chagasâ€™ disease -
An echo from youth. Ugeskrift for Laeger 2000, 162:2567-2569.
9. Frank M, Hegenscheid B, Janitschke K, Weinke T: Prevalence and
epidemiological significance of Trypanosoma cruzi infection among Latin
American immigrants in Berlin, Germany. Infection 1997, 25:355.
Brasil et al. BMC Infectious Diseases 2010, 10:337
http://www.biomedcentral.com/1471-2334/10/337
Page 13 of 17

10. Ochs DE, Hnilica VS, Moser DR, Smith JH, Kirchhoff LV: Postmortem
diagnosis of autochthonous acute chagasic myocarditis by polymerase
chain reaction amplification of a species-specific DNA sequence of
Trypanosoma cruzi. Am J Trop Med Hyg 1996, 54:526.
11. Nabity MB, Barnhart K, Logan KS, Santos RL, Kessell A, Melmed C,
Snowden KF: An atypical case of Trypanosoma cruzi infection in a young
English Mastiff. Veterinary Parasitology 2006, 140:356.
12. Young C, Losikoff P, Chawla A, Glasser L, Forman E: Transfusion-acquired
Trypanosoma cruzi infection. Transfusion 2007, 47:540.
13. Florian Sanz F, Gomez Navarro C, Castrillo Garcia N, Pedrote Martinez A,
Lage Galle E: Chagasic cardiomyopathy in Spain: A diagnosis to bear in
mind. [Spanish]. Anales de Medicina Interna 2005, 11:538-540.
14. Riera C, Guarro A, El Kassab H, Jorba JM, Castro M, Angrill R, Gallego M,
Fisa R, Martin C, Lobato A, Portus M: Congenital transmission of
Trypanosoma cruzi in Europe (Spain): A case report. Am J Trop Med Hyg
2006, 75:1078.
15. [Brazilian Consensus on Chagas disease]. Revista Da Sociedade Brasileira
De Medicina Tropical 2005, 38(Suppl 3):7-29.
16. El Salvador - MinistÃ©rio de la Salud Publica y Assitencia Social: Norma
TÃ©cnica de PrevenciÃ³n y Control de la Enfermedad de Chagas. Book
Norma TÃ©cnica de PrevenciÃ³n y Control de la Enfermedad de Chagas (Editor
ed.^eds.) City: PAHO; 2007.
17. GuÃ­as clÃ­Ä±nicas de la enfermedad de Chagas. Parte V - DiagnÃ³stico de
LaboratÃ³rio. Rev chil infectol 2008, 25:379-383.
18. Gascon J: [Diagnosis and treatment of imported Chagas disease]. Med
Clin (Barc) 2005, 125:230-235.
19. WHO: Control of Chagas disease: second report of WHO expert
committee. Book Control of Chagas disease: second report of WHO expert
committee (Editor ed.^eds.) City 2002.
20. Blood donor screening for chagas diseaseâ€“United States 2006-2007.
MMWR Morb Mortal Wkly Rep 2007, 56:141-143.
21. Castro E: Chagasâ€™ disease: lessons from routine donation testing.
Transfusion Medicine 2009, 19:16-23.
22. Umezawa ES, Bastos SF, Camargo ME, Yamauchi LM, Santos MR,
Gonzalez A, Zingales B, Levin MJ, Sousa O, Rangel-Aldao R, da Silveira JF:
Evaluation of recombinant antigens for serodiagnosis of Chagasâ€™ disease
in south and central America. Journal Of Clinical Microbiology 1999,
37:1554.
23. Peralta JM, Teixeira MG, Shreffler WG, Pereira JB, Burns JM, Sleath PR,
Reed SG: Serodiagnosis of Chagasâ€™ disease by enzyme-linked
immunosorbent assay using two synthetic peptides as antigens. J Clin
Microbiol 1994, 32:971-974.
24. Lorca M, Child R, Garcia A, Silva M, Martinez L, Jerez G, Toledo I,
Mezzano D: Assessment Of Commercial Kits Used For Chagas-Disease
Detection In Blood-Banks.2. Routine Application. Rev Medica Chile 1994,
122:925.
25. Knecher LM, Rojkin LF, Capriotti GA, Lorenzo LE: Chagasâ€™ disease screening
in blood bank employing enzyme immunoassay. International Journal for
Parasitology 1994, 2:207-211.
26. Chiaramonte MG, Frank FM, Furer GM, Taranto NJ, Margni RA, Malchiodi EL:
Polymerase chain reaction reveals Trypanosoma cruzi infection
suspected by serology in cutaneous and mucocutaneous leishmaniasis
patients. Acta Tropica 1999, 72:295.
27. Chiaramonte MG, Zwirner NW, Caropresi SL, Heredia V, Taranto NJ,
Malchiodi EL: Human leishmaniasis infection in the province of Salta.
Evidence of mixed infection with Trypanosoma cruzi and Leishmania spp.
Med-Buenos Aires 1996, 56:259.
28. Corredor Arjona A, Alvarez Moreno CA, Agudelo CA, Bueno M, Lopez MC,
Caceres E, Reyes P, Duque Beltran S, Gualdron LE, Santacruz MM:
Prevalence of Trypanosoma cruzi and Leishmania chagasi infection and
risk factors in a Colombian indigenous population. Rev Inst Med Trop Sao
Paulo 1999, 41:229-234.
29. Haynes RB, You JJ: The architecture of diagnostic research. In The Evidence
Based of Clinical Diagnosis - Theory and methods of diagnostic research.. 2
edition. Edited by: Knottnerus JA, Buntinx F. BMJ Books; 2009:.
30. Requena JM, Jimenez-Ruiz A, Soto M, Lopez MC, Alonso C: Characterization
of a highly repeated interspersed DNA sequence of Trypanosoma cruzi:
its potential use in diagnosis and strain classification. Mol Biochem
Parasitol 1992, 51:271-280.
31. Sturm NR, Degrave W, Morel C, Simpson L: Sensitive detection and
schizodeme classification of Trypanosoma cruzi cells by amplification of
kinetoplast minicircle DNA sequences: use in diagnosis of Chagasâ€™
disease. Mol Biochem Parasitol 1989, 33:205-214.
32. Whiting PF, Weswood ME, Rutjes AWS, Reitsma JB, Bossuyt PNM, Kleijnen J:
Evaluation of QUADAS, a tool for the quality assessment of diagnostic
accuracy studies. BMC Medical Research Methodology 2006, 6.
33. Whiting P, Rutjes AWS, Reitsma JB, Bossuyt PMM, Kleijnen J: The
development of QUADAS: A tool for the quality assessment of studies of
diagnostic accuracy included in systematic reviews. BMC Medical Research
Methodology 2003, 3:1-13.
34. Leeflang M, Reitsma J, Scholten R, Rutjes A, Di Nisio M, Deeks J, Bossuyt P:
Impact of adjustment for quality on results of metaanalyses of
diagnostic accuracy. Clinical Chemistry 2007, 53:164-172.
35. Whiting P, Harbord R, Kleijnen J: No role for quality scores in systematic
reviews of diagnostic accuracy studies. BMC Medical Research Methodology
2005, 5.
36. Westwood ME, Whiting PF, Kleijnen J: How does study quality affect the
results of a diagnostic meta-analysis? BMC Medical Research Methodology
2005, 5.
37. R Development Core Team: R: A Language and Environment for
Statistical Computing. Book R: A Language and Environment for Statistical
Computing (Editor ed.^eds.), 2.9.2 edition City: R Foundation for Statistical
Computing; 2009.
38. Schwarzer G: meta: Meta-Analysis with R. Book meta: Meta-Analysis with R
(Editor ed.^eds.), R package version 1.1-4 edition. City 2009.
39. Chappell FM, Raab GM, Wardlaw JM: When are summary ROC curves
appropriate for diagnostic meta-analyses? Statistics in Medicine 2009,
28:2653-2668.
40. Higgins JPT, Thompson SG, Deeks JJ, Altman DG: Measuring inconsistency
in meta-analyses. BMJ 2003, 327:557-560.
41. Portela-Lindoso AA, Shikanai-Yasuda MA: [Chronic Chagasâ€™ disease: from
xenodiagnosis and hemoculture to polymerase chain reaction]. Rev
Saude Publica 2003, 37:107-115.
42. da Silveira JF, Umezawa ES, Luquetti AO: Chagas disease: recombinant
Trypanosoma cruzi antigens for serological diagnosis. Trends Parasitol
2001, 17:286-291.
43. Fuchs AP, Fioratti VL, de Mello VA, Boainain E: [Serological diagnosis of
Chagasâ€™ disease. Comparative study of various technics]. Rev Inst Med
Trop Sao Paulo 1980, 22:242-245.
44. Spencer HC, Allain DS, Sulzer AJ, Collins WE: Evaluation of the micro
enzyme-linked immunosorbent assay for antibodies to Trypanosoma
cruzi. Am J Trop Med Hyg 1980, 29:179-182.
45. Kahn T, Corral R, Freilij H, Grinstein S: Detection of circulating immune
complexes, antigens and antibodies by enzyme-linked immunosorbent
assay in human T. cruzi infection. IRCS Medical Science 1983, 11:670.
46. Magnaval JF, Brochier B, Charlet JP, Gonzaga Dos Santos L, Larrouy G:
[Screening for Chagas disease by immunoenzymology: comparison of
ELISA with immunofluorescence and indirect hemagglutination in 976
blood donors]. Rev Fr Transfus Immunohematol 1985, 28:201-213.
47. Schechter M, Luquetti AO, Rezende JM, Rassi A, Miles MA: Further
evaluation of lectin affinity purified glycoprotein (Gp90) in the Enzyme
Linked Immunosorbent-Assay (ELISA) for diagnosis of Trypanosoma cruzi
infection. Trans Roy Soc Trop Med Hyg 1985, 79:637.
48. Gonzalez J, Araya J, Olivares H, Sagua H: [ELISA reaction for the diagnosis
of South American trypanosomiasis. Limit absorbances for reacting and
non-reacting sera]. Bol Chil Parasitol 1986, 41:21-26.
49. Castilla MM, Santos-Gomez M, Guzman-Bracho C, Bautista-Garfias CR: A new
method for diagnosis of Chagasâ€™ disease: diffusion-in-gel enzyme-linked
immunosorbent assay. J Parasitol 1988, 74:805-809.
50. De Hubsch RM, Chiechie N, Comach G, Rangel Aldao R, Gusmao RD:
[Immunoenzyme assay using micro Dot on nitrocellulose (Dot-ELISA) in
the diagnosis of Chagasâ€™ disease. I. Comparative study of 2 antigenic
preparations of Trypanosoma cruzi]. Mem Inst Oswaldo Cruz 1988,
83:277-285.
51. Carbonetto CH, Malchiodi EL, Chiaramonte MG, Zwirner NW, Margni RA:
Detection of anti-Trypanosoma cruzi antibodies by ELISA and dotï¿¾immunobinding assay with formalinized epimastigotes. Revista Argentina
de Microbiologia 1989, 21:79-83.
52. Monteon VM, Sosa T, Reyes PA: Serological tests for American
trypanosomiasis. A comparative study. Revista Latinoamericana de
Microbiologia 1989, 31:35-38.
Brasil et al. BMC Infectious Diseases 2010, 10:337
http://www.biomedcentral.com/1471-2334/10/337
Page 14 of 17

53. Zicker F, Smith PG, Luquetti AO, Oliveira OS: Mass screening for
Trypanosoma cruzi infections using the immunofluorescence, ELISA and
haemagglutination tests on serum samples and on blood eluates from
filter-paper. Bull World Health Organ 1990, 68:465-471.
54. Figueredo-Silva J, Kaneda Y, Tachibana H, Furushima R, Tateno S, Correiaï¿¾Lima FG, Bento DN: Epidemiological survey of Trypanosoma cruzi
infection in north-eastern Brazil using different diagnostic methods. Rev
Inst Med Trop Sao Paulo 1991, 33:193-198.
55. Requejo HI, Nakamura PM, Vaz AJ, Pialarissi CS, Hoshino-Shimizu S,
Matsumoto TK, Nakamura H: Diffusion-in-gel enzyme-linked
immunosorbent assay (DIG-ELISA) for Chagasâ€™ disease serodiagnosis.
Braz J Med Biol Res 1991, 24:471-483.
56. Contreras MC, Salinas P, Sandoval L, Solis F, Rojas A: [Usefulness of the
ELISA-IgG test in sera and filter paper blood eluates in the Chagas
disease immunodiagnosis]. Bol Chil Parasitol 1992, 47:76-81.
57. Lorca M, Child R, Garcia A, Silva M, Osorio J, Atias A: Evaluation Of
Commercially Available Reagents For Diagnosis Of Chagas-Disease In
Blood-Banks. Rev Medica Chile 1992, 120:420.
58. Pan AA, Rosenberg GB, Hurley MK, Schock GJ, Chu VP, Aiyappa A: Clinical
evaluation of an EIA for the sensitive and specific detection of serum
antibody to Trypanosoma cruzi (Chagasâ€™ disease). The Journal of Infectious
Diseases 1992, 165:585-588.
59. Petray P, Bonardello N, Clark R, Agranatti M, Corral R, Grinstein S: Elisa
technique for detection of Trypanosoma cruzi circulating antigens and
immune-complexes in San Luis, Argentina. Revista Do Instituto De
Medicina Tropical De Sao Paulo 1992, 34:141.
60. Schattschneider W, Lopes ER, De Alencar JE, Bienzle U, Feldmeier H: A
comparative study of four serological methods for diagnosis of acute
and chronic Chagasâ€™ disease in Brazilian patients. Trop Geogr Med 1992,
44:210-218.
61. Carvalho MR, Krieger MA, Almeida E, Oelemann W, Shikanai-Yassuda MA,
Ferreira AW, Pereira JB, Saez-Alquezar A, Dorlhiac-Llacer PE, Chamone DF,
et al: Chagasâ€™ disease diagnosis: evaluation of several tests in blood
bank screening. Transfusion 1993, 33:830-834.
62. Ramos-Echevarria AA, Monteon-Padilla VM, Reyes-Lopez PA: [Detection of
antibodies against Trypanosoma cruzi in blood donors]. Salud Publica Mex
1993, 35:56-64.
63. Lissaldo AM, Hoshino-Shimizu S, Umezawa ES, Stolf AM: Alkaline soluble
Trypanosoma cruzi epimastigote antigen (ASEA) applied to Dot-ELISA.
Rev Inst Med Trop Sao Paulo 1994, 36:163-166.
64. Teixeira MdGM, Borges-Pereira J, Peralta J: Evaluation of sorological tests
applied for the detection of Trypanosoma cruzi infection. Rev bras patol
clÃ­n 1994, 133-139, Array.
65. Machado-Coelho GL, Vitor RW, Chiari Cde A, Antunes CM: Validity of
serology for American trypanosomiasis with eluates from filter paper.
Mem Inst Oswaldo Cruz 1995, 90:59-64.
66. Solana ME, Katzin AM, Umezawa ES, Miatello CS: High specificity of
Trypanosoma cruzi epimastigote ribonucleoprotein as antigen in
serodiagnosis of Chagasâ€™ disease. Journal of Clinical Microbiology 1995,
6:1456-1460.
67. Tambourgi DV, Cavinato RA, De Abreu CM, Peres BA, Kipnis TL: Detection
of Trypanosoma-decay accelerating factor antibodies in mice and
humans infected with Trypanosoma cruzi. Am J Trop Med Hyg 1995,
52:516-520.
68. Winkler MA, Brashear RJ, Hall HJ, Schur JD, Pan AA: Detection Of
Antibodies To Trypanosoma-Cruzi Among Blood-Donors In The
Southwestern And Western United-States.2. Evaluation Of A
Supplemental Enzyme-Immunoassay And Radioimmunoprecipitation
Assay For Confirmation Of Seroreactivity. Transfusion 1995, 35:219.
69. Avila JL, Rojas M, Avila A: Cholesterol sulphate-reactive autoantibodies are
specifically increased in chronic chagasic human patients. Clinical and
Experimental Immunology 1996, 1:40-46.
70. Corral RS, Altcheh J, Alexandre SR, Grinstein S, Freilij H, Katzin AM:
Detection and characterization of antigens in urine of patients with
acute, congenital, and chronic Chagasâ€™ disease. Journal Of Clinical
Microbiology 1996, 34:1957.
71. Almeida IC, Covas DT, Soussumi LM, Travassos LR: A highly sensitive and
specific chemiluminescent enzyme-linked immunosorbent assay for
diagnosis of active Trypanosoma cruzi infection. Transfusion 1997,
37:850-857.
72. Aznar C, Liegeard P, Mariette C, Lafon S, Levin MJ, Hontebeyrie M: A simple
Trypanosoma cruzi enzyme-linked immunoassay for control of human
infection in nonendemic areas. FEMS Immunol Med Microbiol 1997, 18:31.
73. Hamerschlak N, Pasternak J, Amato Neto V, de Carvalho MB, Guerra CS,
Coscina AL, Ferreira OC, Rosenblit J, Szterling LN: Chagasâ€™ disease: an
algorithm for donor screening and positive donor counseling. Rev Soc
Bras Med Trop 1997, 30:205-209.
74. Monteon VM, Guzman-Rojas L, Negrete-Garcia C, Rosales-Encina JL,
Lopez PA: Serodiagnosis of American trypanosomosis by using
nonpathogenic trypanosomatid antigen. J Clin Microbiol 1997,
35:3316-3319.
75. Alberti Amador E, Fachado Carvajales A, Montalvo AM, Izquierdo Perez LA,
Fonte Galindo L: [Cysteine-dependent protease in Trypanosoma cruzi
useful for the diagnosis of Chagas disease]. Rev Cubana Med Trop 1998,
50:75-81.
76. Krautz GM, Peterson JD, Godsel LM, Krettli AU, Engman DM: Human
antibody responses to Trypanosoma cruzi 70-kD heat-shock proteins. Am
J Trop Med Hyg 1998, 58:137-143.
77. Oelemann WM, Teixeira MD, Verissimo Da Costa GC, Borges-Pereira J, De
Castro JA, Coura JR, Peralta JM: Evaluation of three commercial enzymeï¿¾linked immunosorbent assays for diagnosis of Chagasâ€™ disease. J Clin
Microbiol 1998, 36:2423-2427.
78. Partel CD, Rossi CL: A rapid, quantitative enzyme-linked immunosorbent
assay (ELISA) for the immunodiagnosis of Chagasâ€™ disease. Immunol
Invest 1998, 27:89.
79. Betonico GN, Miranda EO, Silva DA, Houghton R, Reed SG, Campos-Neto A,
Mineo JR: Evaluation of a synthetic tripeptide as antigen for detection of
IgM and IgG antibodies to Trypanosoma cruzi in serum samples from
patients with Chagas disease or viral diseases. Trans R Soc Trop Med Hyg
1999, 93:603-606.
80. Houghton RL, Benson DR, Reynolds LD, McNeill PD, Sleath PR, Lodes MJ,
Skeiky YA, Leiby DA, Badaro R, Reed SG: A multi-epitope synthetic peptide
and recombinant protein for the detection of antibodies to
Trypanosoma cruzi in radioimmunoprecipitation-confirmed and
consensus-positive sera. J Infect Dis 1999, 179:1226-1234.
81. Pinho RT, Pedrosa RC, Costa-Martins P, Castello-Branco LRR: Saliva ELISA: a
method for the diagnosis of chronic Chagas disease in endemic areas.
Acta Trop 1999, 72:31.
82. Leiby DA, Wendel S, Takaoka DT, Fachini RM, Oliveira LC, Tibbals MA:
Serologic testing for Trypanosoma cruzi: Comparison of
radioimmunoprecipitation assay with commercially available indirect
immunofluorescence assay, indirect hemagglutination assay, and
enzyme-linked immunosorbent assay kits. Journal Of Clinical Microbiology
2000, 38:639.
83. Palacios X, Belli A, Espino AM: [Detection of antibodies against
Trypanosoma cruzi in Somoto, Nicaragua, using indirect ELISA and IFI on
blood samples on filter paper]. Rev Panam Salud Publica 2000, 8:411-417.
84. Pereira VR, Nakazawa M, Furtado VC, Abath FG, Gomes YM:
Immunodiagnosis of chronic Chagasâ€™ disease using the Tc 46 and Tc 58
antigens. Rev Soc Bras Med Trop 2000, 33:367-370.
85. Ferreira AW, Belem ZR, Lemos EA, Reed SG, Campos-Neto A: Enzymeï¿¾linked immunosorbent assay for serological diagnosis of Chagasâ€™ disease
employing a Trypanosoma cruzi recombinant antigen that consists of
four different peptides. J Clin Microbiol 2001, 39:4390-4395.
86. Nakazawa M, Rosa DS, Pereira VR, Moura MO, Furtado VC, Souza WV,
Barros MN, Abath FG, Gomes YM: Excretory-secretory antigens of
Trypanosoma cruzi are potentially useful for serodiagnosis of chronic
Chagasâ€™ disease. Clin Diagn Lab Immunol 2001, 8:1024-1027.
87. Sanchez B, Monteon V, Reyes PA, Espinoza B: Standardization of Microï¿¾Enzyme-Linked Immunosorbent Assay (ELISA) and Western blot for
detection of Trypanosoma cruzi antibodies using extracts from Mexican
strains as Antigens. Archives of Medical Research 2001, 32:382.
88. Umezawa ES, Nascimento MS, Stolf AM: Enzyme-linked immunosorbent
assay with Trypanosoma cruzi excreted-secreted antigens (TESA-ELISA)
for serodiagnosis of acute and chronic Chagasâ€™ disease. Diagn Microbiol
Infect Dis 2001, 39:169-176.
89. Cannova D, Aguilar CM, Pacheco M, Simons MI, Medina M: Validation of
enzime-linked immunosorbert assay (ELISA) and indirect
hemagglutination (IHA) for serodiagnosis of chagasâ€™ disease. [Spanish].
Salus 2002, 3:4-9.
Brasil et al. BMC Infectious Diseases 2010, 10:337
http://www.biomedcentral.com/1471-2334/10/337
Page 15 of 17

90. Gadelha AA, Vercosa AF, Lorena VM, Nakazawa M, Carvalho AB, Souza WV,
Ferreira AG, Silva ED, Krieger MA, Goldenberg S, Gomes YM: Chagasâ€™
disease diagnosis: comparative analysis of recombinant ELISA with
conventional ELISA and the haemagglutination test. Vox Sang 2003,
85:165-170.
91. Marcipar IS, Welchen E, Roodveldt C, Marcipar AJ, Silber AM: Purification of
the 67-kDa lectin-like glycoprotein of Trypanosoma cruzi, LLGP-67, and
its evaluation as a relevant antigen for the diagnosis of human
infection. FEMS Microbiol Lett 2003, 220:149-154.
92. Umezawa ES, Bastos SF, Coura JR, Levin MJ, Gonzalez A, Rangel-Aldao R,
Zingales B, Luquetti AO, da Silveira JF: An improved serodiagnostic test
for Chagasâ€™ disease employing a mixture of Trypanosoma cruzi
recombinant antigens. Transfusion 2003, 43:91.
93. Arrieta R, Daquino B, Rosso N, Ferreras MG, Juarez N: Evaluation of a
screening method for Chagas disease in San Luis, Argentina. Salud
Publica Mexico 2004, 46:430.
94. Berrizbietia M, Ndao M, Gottschalk M, Ache A, Vasquez F, Lacouture S,
Medina M, Ward BJ: Development and comparison of enzyme
immunoassays for diagnosis of Chagasâ€™ disease using fixed forms of
Trypanosoma cruzi (epimastigotes, amastigotes, and trypomastigotes)
and assessment of antigen stability for the three assays. Journal Of
Clinical Microbiology 2004, 42:1766.
95. Enciso C, Montilla M, Santacruz MM, Nicholls RS, Rodriguez A, Mercado M,
Puerta C: [Comparison of the indirect immunofluorescent (IFAT), ELISA
test and the comercial Chagatek test for anti-Trypanosoma cruzi
antibodies detection]. Biomedica 2004, 24:104-108.
96. Moretti E, Basso B, Gil P, Vaca B, Jacqueline J, Yasenzaniro P: Detection of
antibodies to Trypanosoma cruzi and Toxoplasma gondii in oral mucosal
transudate. Acta Bioquim Clin Latinoam 2004, 38:159.
97. Umezawa ES, Luquetti AO, Levitus G, Ponce C, Ponce E, Henriquez D,
Revollo S, Espinoza B, Sousa O, Khan B, da Silveira JF: Serodiagnosis of
chronic and acute Chagasâ€™ disease with Trypanosoma cruzi recombinant
proteins: Results of a collaborative study in six Latin American countries.
J Clin Microbiol 2004, 42:449.
98. Pirard M, Iihoshi N, Boelaert M, Basanta P, Lopez F, Van der Stuyft P: The
validity of serologic tests for Trypanosoma cruzi and the effectiveness of
transfusional screening strategies in a hyperendemic region. Transfusion
2005, 45:554.
99. Berrizbeitia M, Ndao M, Bubis J, Gottschalk M, Ache A, Lacouture S,
Medina M, Ward BJ: Purified excreted-secreted antigens from
Trypanosoma cruzi trypomastigotes as tools for diagnosis of Chagasâ€™
disease. Journal Of Clinical Microbiology 2006, 44:291.
100. Duarte AM, de Andrade HM, do Monte SJ, de Toledo Vde P, Guimaraes TM:
Assessment of chemiluminescence and PCR effectiveness in relation to
conventional serological tests for the diagnosis of Chagasâ€™ disease. Rev
Soc Bras Med Trop 2006, 39:385-387.
101. Kirchhoff LV, Paredes P, Lomeli-Guerrero A, Paredes-Espinoza M, Ronï¿¾Guerrero CS, Delgado-Mejia M, Pena-Munoz JG: Transfusion-associated
Chagas disease (American trypanosomiasis) in Mexico: implications for
transfusion medicine in the United States. Transfusion 2006, 46:298.
102. Malan AK, Avelar E, Litwin SE, Hill HR, Litwin CM: Serological diagnosis of
Trypanosoma cruzi: evaluation of three enzyme immunoassays and an
indirect immunofluorescent assay. J Med Microbiol 2006, 55:171.
103. Caballero ZC, Sousa OE, Marques WP, Saez-Alquezar A, Umezawa ES:
Evaluation of serological tests to identify Trypanosoma cruzi infection in
humans and determine cross-reactivity with Trypanosoma rangeli and
Leishmania spp. Clinical And Vaccine Immunology 2007, 14:1045.
104. Tobler LH, Contestable P, Pitina L, Groth H, Shaffer S, Blackburn GR,
Warren H, Lee SR, Busch MP: Evaluation of a new enzyme-linked
immunosorbent assay for detection of Chagas antibody in US blood
donors. Transfusion 2007, 47:90.
105. Gorlin J, Rossmann S, Robertson G, Stallone F, Hirschler N, Nguyen KA,
Gilcher R, Fernandes H, Alvey S, Ajongwen P, et al: Evaluation of a new
Trypanosoma cruzi antibody assay for blood donor screening. Transfusion
2008, 48:531-540.
106. Almeida E, Krieger MA, Carvalho MR, Oelemann W, Goldenberg S: Use of
recombinant antigens for the diagnosis of Chagas disease and blood
bank screening. Mem Inst Oswaldo Cruz 1990, 85:513-517.
107. dos Santos CND, Krieger MA, Almeida E, Lafaille JJ, Goldenberg S, Galler R:
Trypanosoma cruzi flagellar repetitive antigen expression by
recombinant baculovirus: Towards an improved diagnostic reagent for
chagasâ€™ disease. Nature Biotechnology 1992, 10:1474.
108. Cetron MS, Hoff R, Kahn S, Eisen H, Van Voorhis WC: Evaluation of
recombinant trypomastigote surface antigens of Trypanosoma cruzi in
screening sera from a population in rural northeastern Brazil endemic
for Chagasâ€™ disease. Acta Trop 1992, 50:259-266.
109. Breniere SF, Yaksic N, Telleria J, Bosseno MF, Noireau F, Wincker P,
Sanchez D: Immune response to Trypanosoma cruzi shed acute phase
antigen in children from an endemic area for Chagasâ€™ disease in Bolivia.
Mem Inst Oswaldo Cruz 1997, 92:503.
110. Meira WS, Galvao LM, Gontijo ED, Machado-Coelho GL, Norris KA, Chiari E:
Trypanosoma cruzi recombinant complement regulatory protein: a novel
antigen for use in an enzyme-linked immunosorbent assay for diagnosis
of Chagasâ€™ disease. J Clin Microbiol 2002, 40:3735-3740.
111. Marcipar IS, Olivares ML, Robles L, Dekanty A, Marcipar A, Silber AM: The
diagnostic performance of recombinant Trypanosoma cruzi ribosomal P2
beta protein is influenced by its expression system. Protein Expr Purif
2004, 34:1.
112. Marcipar IS, Roodveldt C, Corradi G, Cabeza ML, Brito ME, Winter LM,
Marcipar AJ, Silber AM: Use of full-length recombinant calflagin and its c
fragment for improvement of diagnosis of Trypanosoma cruzi infection. J
Clin Microbiol 2005, 43:5498-5503.
113. Hernandez Marin M, Hernandez Spengler I, Ramos Martinez G, Pozo Pena L:
Chimeric synthetic peptides as antigens for detection of antibodies to
Trypanosoma cruzi. Biochem Biophys Res Commun 2006, 339:89-92.
114. Chang CD, Cheng KY, Jiang LX, Salbilla VA, Haller AS, Yem AW, Bryant JD,
Kirchhoff LV, Leiby DA, Schochetman G, Shah DO: Evaluation of a
prototype Trypanosoma cruzi antibody assay with recombinant antigens
on a fully automated chemiluminescence analyzer for blood donor
screening. Transfusion 2006, 46:1737.
115. Gomes YM, Pereira VRA, Nakazawa M, Rosa DS, Barros MDNDS, Ferreira AGP,
Silva ED, Yamada Ogatta SF, Krieger MA, Goldenberg S: Serodiagnosis of
Chronic Chagas Infection by Using EIE-Recombinant-Chagasï¿¾Biomanguinhos Kit. Mem Inst Oswaldo Cruz 2001, 96:497.
116. Pastini AC, Iglesias SR, Carricarte VC, Guerin ME, Sanchez DO, Frasch AC:
Immunoassay With Recombinant Trypanosoma-Cruzi Antigens
Potentially Useful For Screening Donated Blood And Diagnosing
Chagas-Disease. Clinical Chemistry 1994, 40:1893.
117. Avila HA, Pereira JB, Thiemann O, De Paiva E, DeGrave W, Morel CM,
Simpson L: Detection of Trypanosoma cruzi in blood specimens of
chronic chagasic patients by polymerase chain reaction amplification of
kinetoplast minicircle DNA: comparison with serology and
xenodiagnosis. J Clin Microbiol 1993, 31:2421-2426.
118. Wincker P, Britto C, Pereira JB, Cardoso MA, Oelemann W, Morel CM: Use of
a simplified polymerase chain reaction procedure to detect
Trypanosoma cruzi in blood samples from chronic chagasic patients in a
rural endemic area. Am J Trop Med Hyg 1994, 6:771-777.
119. Britto C, Cardoso MA, Vanni CM, Hasslocher-Moreno A, Xavier SS,
Oelemann W, Santoro A, Pirmez C, Morel CM, Wincker P: Polymerase chain
reaction detection of Trypanosoma cruzi in human blood samples as a
tool for diagnosis and treatment evaluation. Parasitology 1995, 110(Pt
3):241-247.
120. Espinoza AG, Taibi A, BillautMulot O, Ouaissi A: PCR-based detection of
Trypanosoma cruzi useful for specific diagnosis of human Chagasâ€™
disease. J Clin Microbiol 1996, 34:485.
121. Junqueira AC, Chiari E, Wincker P: Comparison of the polymerase chain
reaction with two classical parasitological methods for the diagnosis of
Chagas disease in an endemic region of north-eastern Brazil. Trans R Soc
Trop Med Hyg 1996, 90:129-132.
122. Wincker P, Telleria J, Bosseno MF, Cardoso MA, Marques P, Yaksic N,
Aznar C, Liegeard P, Hontebeyrie M, Noireau F, et al: PCR-based diagnosis
for Chagasâ€™ disease in Bolivian children living in an active transmission
area: Comparison with conventional serological and parasitological
diagnosis. Parasitology 1997, 114:367.
123. Carriazo CS, Sembaj A, Aguerri AM, Requena JM, Alonso C, Bua J, Ruiz A,
Segura E, Barral JM: Polymerase chain reaction procedure to detect
Trypanosoma cruzi in blood samples from chronic chagasic patients.
Diagn Microbiol Infect Dis 1998, 30:183.
124. Gomes ML, Galvao LM, Macedo AM, Pena SD, Chiari E: Chagasâ€™ disease
diagnosis: comparative analysis of parasitologic, molecular, and
serologic methods. Am J Trop Med Hyg 1999, 60:205-210.
Brasil et al. BMC Infectious Diseases 2010, 10:337
http://www.biomedcentral.com/1471-2334/10/337
Page 16 of 17

125. Ribeiro-Dos-Santos G, Nishiya AS, Sabino EC, Chamone DF, Saez-Alquezar A:
An improved, PCR-based strategy for the detection of Trypanosoma cruzi
in human blood samples. Ann Trop Med Parasitol 1999, 93:689.
126. Castro AM, Luquetti AO, Rassi A, Rassi GG, Chiari E, Galvao LM: Blood
culture and polymerase chain reaction for the diagnosis of the chronic
phase of human infection with Trypanosoma cruzi. Parasitol Res 2002,
88:894-900.
127. Gutierrez R, Angulo VM, Tarazona Z, Britto C, Fernandes O: Comparison of
four serological tests for the diagnosis of Chagas disease in a
Colombian endemic area. Parasitology 2004, 129:439.
128. Piron M, Fisa R, Casamitjana N, Lopez-Chejade P, Puig L, Verges M,
Gascon J, Prat JG, Portus M, Sauleda S: Development of a real-time PCR
assay for Trypanosoma cruzi detection in blood samples. Acta Trop 2007,
103:195-200.
129. Gil J, Pavia P, Montilla M, Florez AC, Quintero C, Mercado M, Vacca M,
Nicholls S, Puerta C: [Comparison of a PCR test based on the histone
H2A/SIRE genes with classical serological tests for the diagnosis of
chronic Chagas disease in Colombian patients]. Biomedica 2007, 27(Suppl
1):83-91.
130. Fitzwater S, Calderon M, Lafuente C, Galdos-Cardenas G, Ferrufino L,
Verastegui M, Gilman RH, Bern C: Polymerase chain reaction for chronic
Trypanosoma cruzi infection yields higher sensitivity in blood clot than
buffy coat or whole blood specimens. Am J Trop Med Hyg 2008,
79:768-770.
131. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM,
Lijmer JG, Moher D, Rennie D, De Vet HCW: Towards complete and
accurate reporting of studies of diagnostic accuracy: The STARD
initiative. British Medical Journal 2003, 326:41-44.
132. Who, how, what and where?. Nature 465:S8-S9.
133. Bucio MI, Cabrera M, Segura EL, Zenteno E, Salazar-Schettino M:
Identification of immunodominant antigens in Mexican strains of
Trypanosoma cruzi. Immunol Invest 1999, 28:257-268.
134. Verani JR, Seitz A, Gilman RH, LaFuente C, Galdos-Cardenas G, Kawai V, de
LaFuente E, Ferrufino L, Bowman NM, Pinedo-Cancino V, et al: Geographic
variation in the sensitivity of recombinant antigen-based rapid tests for
chronic Trypanosoma cruzi infection. Am J Trop Med Hyg 2009, 80:410-415.
135. Monteon VM, Guzman-Bracho C, Floriani-Verdugo J, Ramos-Echevarria A,
Velasco-Castrejon O, Reyes PA: [Serological diagnosis of Chagas disease:
self-sufficiency and interlaboratory concordance]. Salud Publica Mex 1995,
37:232-235.
136. Reliability (statistics). [http://en.wikipedia.org/wiki/Reliability_%28statistics%
29].
137. Irwig LM, Bossuyt PMM, Glasziou PP, Gatsonis C, Lijmer JG: Designing
studies to ensure that estimates of test accuracy will travel. In The
Evidence Based of Clinical Diagnosis - Theory and methods of diagnostic
research.. 2 edition. Edited by: Knottnerus JA, Buntinx F. BMJ Books; .
138. Kinetoplast Minicircle Sequence Database. [http://www.ebi.ac.uk/parasites/
kDNA/Source.html].
139. Coronado X, Ortiz S, Lastra O, Larrondo M, Rozas M, Solari A: Instability of
Trypanosoma cruzi DNA in blood lysates: importance for PCR DNA-based
diagnosis. Mol Diagn 2005, 9:35-40.
140. Dorn PL, Selgean S, Guillot M: Simplified method for preservation and
polymerase chain reaction-amplification of Trypanosoma cruzi DNA in
human blood. Mem Inst Oswaldo Cruz 1997, 92:253-255.
141. Castro C, MacÃªdo V, Prata A: Comportamento da parasitemia pelo
Trypanosoma cruzi em chagÃ¡sicos crÃ´nicos durante 13 anos. Revista da
Sociedade Brasileira de Medicina Tropical 1999, 32.
142. Castro C, Prata A: Absence of both circadian rhythm and Trypanosoma
cruzi periodicity with xenodiagnosis in chronic chagasic individuals.
Revista da Sociedade Brasileira de Medicina Tropical 2000, 33.
143. Britto C, Cardoso A, Silveira C, Macedo V, Fernandes O: Polymerase chain
reaction (PCR) as a laboratory tool for the evaluation of the
parasitological cure in Chagas disease after specific treatment. Medï¿¾Buenos Aires 1999, 59:176.
144. Duffy T, Bisio M, Altcheh J, Burgos JM, Diez M, Levin MJ, Favaloro RR,
Freilij H, Schijman AG: Accurate real-time PCR strategy for monitoring
bloodstream parasitic loads in chagas disease patients. PLoS Negl Trop
Dis 2009, 3:e419.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2334/10/337/prepub
doi:10.1186/1471-2334-10-337
Cite this article as: Brasil et al.: ELISA versus PCR for diagnosis of
chronic Chagas disease: systematic review and meta-analysis. BMC
Infectious Diseases 2010 10:337.
Submit your next manuscript to BioMed Central
and take full advantage of: 
â€¢ Convenient online submission
â€¢ Thorough peer review
â€¢ No space constraints or color figure charges
â€¢ Immediate publication on acceptance
â€¢ Inclusion in PubMed, CAS, Scopus and Google Scholar
â€¢ Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Brasil et al. BMC Infectious Diseases 2010, 10:337
http://www.biomedcentral.com/1471-2334/10/337
Page 17 of 17

